Form 8-K

8-K — Sintx Technologies, Inc.

Accession: 0001493152-26-037130

Filed: 2026-08-11

Period: 2026-08-11

CIK: 0001269026

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

GRAPHIC (ex99-1_002.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001269026

2026-08-11

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 11, 2026

SINTX

Technologies, Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-33624

84-1375299

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

1885

West 2100 South

Salt

Lake City, UT 84119

(Address

of principal executive offices, including Zip Code)

Registrant’s

telephone number, including area code: (801) 839-3500

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class:

Trading

Symbol(s):

Name

of each exchange on which registered:

Common

Stock, par value $0.01 per share

SINT

The

NASDAQ Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02 Results of Operations and Financial Condition.

August 11, 2026, SINTX Technologies, Inc. (the “Company”) issued a press release providing a business update in connection

with the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, including certain information regarding the

Company’s results of operations, financial condition and revenue outlook. A copy of the press release is furnished as Exhibit 99.1

to this Current Report on Form 8-K and is incorporated herein by reference.

Item

7.01. Regulation FD Disclosure.

The

information contained in the press release furnished as Exhibit 99.1 also includes updates regarding the Company’s commercialization

activities, customer purchase orders, product-development programs, strategic initiatives and other business matters.

The

information furnished pursuant to Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed

“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities

of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as

amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item

9.01 Financial Statements and Exhibits.

Exhibit

No.

Description

99.1

Press Release dated August 11, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

SINTX

Technologies, Inc.

Date:

August

11, 2026

By:

/s/

Eric K. Olson

Eric

K. Olson

Chief

Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

SINTX

Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth

Initiatives

SALT

LAKE CITY, Utah – August 11, 2026 – SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”),

a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today provided a business update

in conjunction with the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.

During

the first half of 2026, SINTX advanced the commercialization of its FDA-cleared SiNAPTIC® Foot & Ankle Implant System,

expanded its commercial distribution network, raised additional capital, invested in advanced manufacturing capabilities, and continued

to broaden the application of its proprietary silicon nitride technology platform across multiple healthcare and industrial markets.

These

accomplishments reflect the Company’s strategic transition from technology development toward commercial execution while continuing

to build a diversified portfolio of growth opportunities designed to create long-term shareholder value.

“Our

strategy has always extended well beyond the introduction of a single medical device,” said Eric K. Olson, Chairman, President

and Chief Executive Officer of SINTX Technologies. “During the first half of 2026, we continued building the commercial infrastructure,

manufacturing capabilities, and strategic relationships necessary to support our growth strategy, while raising additional capital and

implementing measures designed to preserve liquidity and improve operating efficiency. We believe silicon nitride represents a differentiated

technology platform with the potential to address multiple high-value healthcare and industrial markets, and we remain focused on translating

these investments into increasing commercial adoption, expanding revenue opportunities and potential long-term value creation.”

Commercial

Execution Accelerates

Following

FDA 510(k) clearance in October 2025, SINTX initiated a Limited Use Release (“LUR”) of its SiNAPTIC® Foot

& Ankle Osteotomy Wedge System during the first half of 2026. The LUR is intended to support surgeon training, clinical adoption

and commercialization ahead of broader market expansion.

support this commercialization effort, the Company established its initial network of twelve independent orthopedic distributors specializing

in foot and ankle surgery. As surgeon adoption continues to expand, SINTX expects this commercial infrastructure to support broader market

penetration throughout the United States.

The

Company believes SiNAPTIC’s proprietary silicon nitride biomaterial offers meaningful clinical differentiation through its demonstrated

bone affinity and inherent resistance to bacterial adhesion, characteristics that position the platform for potential expansion into

additional orthopedic applications.

Multiple

Revenue Opportunities Continue to Expand

While

advancing commercialization of its medical technologies, SINTX continued to expand its established industrial ceramics business.

During

the first half of 2026, the Company received approximately $3.2 million in new industrial purchase orders from multiple contract manufacturing

customers for the production of advanced ceramic components serving demanding, high-performance applications. Initial shipments have

commenced, and the Company currently expects to recognize revenue associated with these purchase orders beginning in the third quarter

of 2026, subject to delivery schedules, customer acceptance and applicable revenue-recognition requirements.

Management

believes the industrial business provides an important commercial foundation that supports continued investment in higher-growth medical

technologies while diversifying the Company’s revenue base.

Revenue

Outlook for the Second Half of 2026

Reflecting

increased commercial activity and the commencement of production and shipments associated with previously announced customer purchase

orders, SINTX currently expects total revenue to be approximately $900,000 to $1.1 million for the third quarter of 2026 and approximately

$1.0 million to $1.3 million for the fourth quarter of 2026.

This

outlook is based on current production schedules, customer requirements and management’s expectations regarding manufacturing execution,

shipments and the timing of revenue recognition. The Company’s outlook is subject to significant uncertainty, including potential

changes in customer schedules, material availability, manufacturing yield and capacity, quality release, shipment timing, customer acceptance

and product mix. Accordingly, actual results could differ materially from these expectations.

The

Company continues to view the approximately $3.2 million of previously announced industrial purchase orders as an important source of

commercial visibility, while recognizing that purchase-order value does not represent guaranteed revenue and that the timing of revenue

recognition will depend on successful execution and satisfaction of applicable accounting criteria.

Beyond

its existing commercial businesses, SINTX continues to expand the potential applications of its silicon nitride technology platform through

multiple product development initiatives, including silicon nitride-infused sutures, advanced wound care products, SiN/PEEK composite

implants, and other next-generation orthopedic technologies.

Animal

studies evaluating the Company’s antipathogenic suture and wound care technologies are currently scheduled to begin during the

third quarter of 2026, with preliminary data expected to be available for potential licensing partners before year-end, subject to

study initiation, execution and timing.

Advanced

Manufacturing Platform Supports Future Growth

During

the first half of 2026, SINTX completed construction of its advanced 3D printing manufacturing facility intended to support the future

production of SiNERGY™ patient-specific and custom silicon nitride/PEEK orthopedic implants.

The

new manufacturing capability expands the Company’s vertically integrated production platform while positioning SINTX to pursue

future opportunities in personalized orthopedic reconstruction and other high-value medical applications.

The

Company also continues to advance development of porous silicon nitride/PEEK spinal fusion implants through its National Institutes of

Health (“NIH”) research grant. Recently, SINTX received notice from the NIH granting SINTX an additional twelve-month

period to access the approximately $745,000 remaining on the final phase of its $1.97 million NIH grant, further supporting development

of next-generation spinal implant technologies.

Capital

Resources and Cost Management Initiatives

During

the second quarter, SINTX completed financing transactions that generated approximately $5.0 million in gross proceeds, consisting primarily

of a private placement and sales under its existing At-The-Market (“ATM”) facility.

The

proceeds provided additional capital to support the Company’s commercialization activities, manufacturing operations, product development

initiatives and general corporate purposes. The Company also continues to have additional capacity available under its existing ATM facility,

subject to market conditions, applicable securities-law requirements and the terms of the program.

SINTX

continues to manage its liquidity carefully. In parallel with its commercialization and development activities, management has initiated

a capital allocation and cost optimization initiative focused on improving operating efficiency, reducing discretionary spending and

prioritizing expenditures that management believes are most directly related to commercialization and revenue generation.

The

Company’s ability to execute its business plan remains dependent on its ability to manage operating expenses, increase revenue

and obtain additional financing when needed. Management believes that disciplined capital allocation and cost management are important

to preserving liquidity and supporting the Company’s highest-priority commercial and development programs.

Strategic

Platform Continues to Attract Industry Interest

Recognizing

the expanding commercial opportunities surrounding its silicon nitride technology platform, SINTX recently engaged Chris Lyons of Southern

Metrics to coordinate and evaluate inbound strategic opportunities involving potential commercial partnerships, licensing relationships

and other business development initiatives.

The

Company believes strategic collaborations represent an important opportunity to accelerate commercialization while leveraging its intellectual

property portfolio across multiple healthcare and industrial markets.

Expanded

Equity Research Coverage

During

the first half of 2026, H.C. Wainwright & Co. and Maxim Group initiated equity research coverage of SINTX with Buy ratings. The Company

believes broader research coverage may increase investor awareness of its differentiated technology platform, commercialization strategy

and long-term growth opportunities.

Looking

Ahead

Management

believes the first half of 2026 established several important building blocks for the Company’s next phase of growth, including

commercialization of the SiNAPTIC platform, expansion of its commercial distribution network, investment in advanced manufacturing capabilities,

continued development of next-generation silicon nitride technologies, raising additional capital and implementing capital-allocation

and cost-management initiatives.

With

multiple commercial and development programs advancing simultaneously, SINTX believes its proprietary silicon nitride technology platform

will provide opportunities across orthopedic implants, industrial ceramics, personalized medical devices, silicon nitride/PEEK composites

and antipathogenic medical products.

About

SINTX

Headquartered

in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics company that develops, manufactures, and commercializes

silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. SINTX’s

technologies are supported by peer-reviewed research, a patent portfolio, U.S.-based manufacturing capabilities and strategic industry

relationships. The Company’s business includes proprietary biomaterials and medical device technologies, as well as contract manufacturing

and other advanced ceramics opportunities. SINTX’s product portfolio includes the FDA-cleared SiNAPTIC® Foot &

Ankle Osteotomy Wedge System for reconstructive surgery.

NIH

Funding Acknowledgment: Research described in this press release relating to the Company’s 3D-printed silicon nitride porous

PEEK composite spinal cage program is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National

Institutes of Health under Award Number R44AR083836. The content is solely the responsibility of SINTX Technologies, Inc. and does not

necessarily represent the official views of the National Institutes of Health.

Forward-Looking

Statements

This

press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including

statements regarding: the commercialization, market introduction and potential adoption of the SiNAPTIC® Foot & Ankle Osteotomy

Wedge System; the expansion and effectiveness of the Company’s distributor network; the clinical and commercial potential of silicon

nitride and the possible expansion of the Company’s technology into additional medical and industrial applications; anticipated

shipments and the timing and amount of revenue recognition associated with industrial purchase orders; the Company’s revenue guidance

and expectations regarding the amount and timing of revenue for the third and fourth quarters of 2026; the timing, conduct and results

of animal studies and other research and development activities; the availability of preliminary data to potential licensing or strategic

partners; the capabilities and potential commercial applications of the Company’s advanced manufacturing platform; the development

of patient-specific, custom and silicon nitride/PEEK implants; the identification, evaluation and consummation of potential commercial

partnerships, licensing arrangements, strategic investments, acquisitions, divestitures or other strategic transactions; the Company’s

liquidity, capital requirements, cost-management initiatives, ability to preserve liquidity, and ability to obtain additional financing;

and the Company’s growth prospects and ability to create long-term shareholder value. These forward-looking statements are based

on management’s current expectations, estimates, projections and assumptions and are subject to significant risks and uncertainties

that could cause actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking

statements. These risks and uncertainties include, among others: the Company’s ability to successfully commercialize its products

and achieve market acceptance; the timing and results of product development, preclinical and clinical activities; the performance of

distributors, suppliers and manufacturing operations; changes in customer demand, purchase orders, shipment schedules or customer acceptance;

the Company’s ability to recognize anticipated revenue; the Company’s limited liquidity and history of operating losses;

its need to obtain additional financing to continue operations and execute its business plan; the availability, timing and terms of any

additional financing; potential dilution resulting from equity financings; the Company’s ability to maintain an effective registration

statement and satisfy the conditions for sales under its ATM offering program; and substantial doubt regarding the Company’s ability

to continue as a going concern; and the other risks described under “Risk Factors” in the Company’s most recent Annual

Report on Form 10-K and Quarterly Reports on Form 10-Q, and in the Company’s other filings with the U.S. Securities and Exchange

Commission. SINTX undertakes no obligation to update forward-looking statements except as required by law.

SINTX

Contacts:

Investor

Relations

Gregg

Honigblum, Chief Investment Officer

801-839-3502

IR@sintx.com

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (2487 bytes)

Download ex99-1_001.jpg

GRAPHIC

Filename: ex99-1_002.jpg · Sequence: 4

Binary file (2133 bytes)

Download ex99-1_002.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Aug. 11, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 11, 2026

Entity File Number

001-33624

Entity Registrant Name

SINTX

Technologies, Inc.

Entity Central Index Key

0001269026

Entity Tax Identification Number

84-1375299

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1885

West 2100 South

Entity Address, City or Town

Salt

Lake City

Entity Address, State or Province

Entity Address, Postal Zip Code

84119

City Area Code

(801)

Local Phone Number

839-3500

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.01 per share

Trading Symbol

SINT

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration